CYP2C19
From Wikipedia, the free encyclopedia
|
cytochrome P450, family 2, subfamily C, polypeptide 19
|
|
| Identifiers | |
| Symbol(s) | CYP2C19 CYP2C |
| Entrez | 1557 |
| OMIM | 124020 |
| RefSeq | NM_000769 |
| UniProt | P33261 |
| Other data | |
| Locus | Chr. 10 q24 |
Cytochrome P450 2C19 (abbreviated CYP2C19), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics.
Genetic polymorphism exists for CYP2C19 expression, with approximately 3–5% of Caucasian and 15–20% of Asian populations being poor metabolisers with no CYP2C19 function.
[edit] CYP2C19 Ligands
| Selected inducers, inhibitors and substrates of CYP2C191 | |
| Type | Agent |
| inducers | carbamazepine, norethindrone, prednisone, rifampicin, St. John's Wort |
| inhibitors | chloramphenicol, cimetidine, fluoxetine, fluvoxamine, indomethacin, ketoconazole, lansoprazole, modafinil, omeprazole, oxcarbazepine, probenecid, ticlopidine, topiramate |
| substrates | amitriptyline, antiepileptics (incl. diazepam, phenytoin, phenobarbital), citalopram, clomipramine, cyclophosphamide, imipramine, indomethacin, moclobemide, nelfinavir, primidone, progesterone, proguanil, propranolol, proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole, etc), teniposide, warfarin |
Notes:
|
|
